Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

被引：0
|
作者：
Harrison, Claire N. [1 ]
Vannucchi, Alessandro M. [2 ]
Kiladjian, Jean-Jacques [3 ,4 ]
Al-Ali, Haifa Kathrin [5 ]
Gisslinger, Heinz [6 ]
Knoops, Laurent [7 ,8 ]
Cervantes, Francisco [9 ]
Jones, Mark M. [10 ]
Sun, Kang [10 ]
Descamps, Laurence [11 ]
Stalbovskaya, Viktoriya [12 ]
Gopalakrishna, Prashanth [12 ]
Barbui, Tiziano [13 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England
[2] Univ Florence, Florence, Italy
[3] Hop St Louis, Paris, France
[4] Univ Paris Diderot, Paris, France
[5] Univ Leipzig, D-04109 Leipzig, Germany
[6] Med Univ Vienna, Vienna, Austria
[7] Clin Univ St Luc, B-1200 Brussels, Belgium
[8] Catholic Univ Louvain, de Duve Inst, B-1200 Brussels, Belgium
[9] Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain
[10] Incyte Corp, Wilmington, DE USA
[11] Novartis Pharma SAS, Rueil Malmaison, France
[12] Novartis Pharma AG, Basel, Switzerland
[13] Hosp Papa Giovanni XXIII & Res Fdn, Bergamo, Italy
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
    Srdan Verstovsek
    Ruben A. Mesa
    Jason Gotlib
    Vikas Gupta
    John F. DiPersio
    John V. Catalano
    Michael W. N. Deininger
    Carole B. Miller
    Richard T. Silver
    Moshe Talpaz
    Elliott F. Winton
    Jimmie H. Harvey
    Murat O. Arcasoy
    Elizabeth O. Hexner
    Roger M. Lyons
    Ronald Paquette
    Azra Raza
    Mark Jones
    Deanna Kornacki
    Kang Sun
    Hagop Kantarjian
    Journal of Hematology & Oncology, 10
  • [32] Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I
    Verstovsek, Srdan
    Mesa, Ruben A.
    Gotlib, Jason
    Levy, Richard S.
    Gupta, Vikas
    Dipersio, John F.
    Catalano, John V.
    Deininger, Michael W.
    Miller, Carole B.
    Silver, Richard T.
    Talpaz, Moshe
    Winton, Elliott F.
    Harvey, Jimmie H., Jr.
    Arcasoy, Murat O.
    Hexner, Elizabeth
    Lyons, Roger M.
    Paquette, Ronald
    Raza, Azra
    Vaddi, Kris
    Sun, William
    Peng, Wei
    Sandor, Victor A.
    Kantarjian, Hagop M.
    BLOOD, 2013, 122 (21)
  • [33] LONG-TERM BELATACEPT MAINTAINS EFFICACY AND SAFETY: 5-YEAR BENEFIT LONG-TERM EXTENSION (LTE) RESULTS
    Rostaing, L.
    Vincenti, F.
    Grinyo, J. M.
    Rice, K. M.
    Steinberg, S. M.
    Gaite, L. E.
    Moal, M. C.
    Pupim, L.
    Larsen, C. P.
    TRANSPLANT INTERNATIONAL, 2013, 26 : 2 - 3
  • [34] LONG-TERM BELATACEPT MAINTAINS EFFICACY & SAFETY: 5-YEAR BENEFIT LONG-TERM EXTENSION (LTE) RESULTS
    Rostaing, Lionel
    Vincenti, Flavio
    Grinyo, Josep M.
    Rice, Kim
    Steinberg, Steven M.
    Gaite, Luis
    Moal, Marie-Christine
    Pupim, Lara
    Larsen, Christian
    TRANSPLANT INTERNATIONAL, 2013, 26 : 44 - 44
  • [35] LONG-TERM EVALUATION OF SECUKINUMAB 150 MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
    Marzo-Ortega, Helena
    Sieper, Joachim
    Kivitz, Alan
    Blanco, Ricardo
    Cohen, Martin
    Pavelka, Karel
    Delicha, Eumorphia Maria
    Stefanska, Anna
    Richards, Hanno
    Rohrer, Susanne
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 873 - 873
  • [36] Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study
    Wong, Raymond S. M.
    Saleh, Mansoor N.
    Khelif, Abderrahim
    Salama, Abdulgabar
    Portella, Maria Socorro O.
    Burgess, Paul
    Bussel, James B.
    BLOOD, 2017, 130 (23) : 2527 - 2536
  • [37] LONG-TERM SAFETY AND EFFICACY OF DEFERASIROX IN PEDIATRIC PATIENTS WITH TRANSFUSIONAL HEMOSIDEROSIS: RESULTS FROM A 5-YEAR OBSERVATIONAL STUDY (ENTRUST)
    Vichinsky, E.
    El Beshlawy, A.
    Alzoebie, A.
    Kamdem, A.
    Koussa, S.
    Chotsampancharoen, T.
    Bruederle, A.
    Gilotti, G.
    Han, J.
    Elalfy, M.
    HAEMATOLOGICA, 2016, 101 : 612 - 612
  • [38] PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY
    Verstovsek, S.
    Vannucchi, A. M.
    Platzbecker, U.
    Cervantes, F.
    Gupta, V.
    Lavie, D.
    Passamonti, F.
    Winton, E. F.
    Dong, H.
    Kawashima, J.
    Maltzman, J. D.
    Kiladjian, J-J.
    Harrison, C. N.
    HAEMATOLOGICA, 2017, 102 : 320 - 321
  • [39] The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study
    Hijiya, Nobuko
    Maschan, Alexey
    Rizzari, Carmelo
    Shimada, Hiroyuki
    Dufour, Carlo
    Goto, Hiroaki
    Kang, Hyoung Jin
    Guinipero, Terri
    Karakas, Zeynep
    Bautista, Francisco
    Ducassou, Stephane
    Yoo, Keon Hee
    Zwaan, Christian Michel
    Millot, Frederic
    Patterson, Briana C.
    Samis, Jill
    Izquierdo, Miguel
    Titorenko, Ksenia
    Li, Sai
    Sosothikul, Darintr
    BLOOD ADVANCES, 2023, 7 (23) : 7279 - 7289
  • [40] Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis
    Klareskog, L.
    Gaubitz, M.
    Rodriguez-Valverde, V.
    Malaise, M.
    Dougados, M.
    Wajdula, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 238 - 247
12345